Lipid nanoparticles (LNPs), used to deliver the mRNA in the COVID-19 vaccine to the body's cells, don't remain in the injection site — they circulate throughout the entire body and reach vital organs, including the heart, according to a new paper published in Nature Biotechnology.
The findings "suggest a potential mechanism by which LNP-based mRNA vaccines could contribute to the reported cardiac complications," including myocarditis, the study authors wrote.
Now published in one of the top scientific journals, the study's findings contradict claims by public health officials and scientists during the COVID-19 vaccine rollouts that the LNPs were safe because they traveled only to specific targeted sites in the body.
The authors said there is no existing adequate technology to trace where nanocarriers such as LNPs end up in the body after they are administered via intramuscular injection — especially for medication like vaccines, which contain low doses of the particles.
In this study, authors developed an experimental technology to trace where different carriers of nanoparticles, including LNPs, end up in the body after intramuscular injection. They tested the technology in mice.
The researchers found that even at extremely low doses, LNPs carrying the SARS-CoV-2 spike protein mRNA reached vital organs. It reached heart tissue and caused cellular or tissue changes....<<<Read More>>>...
